S
ATRA icon

SignatureFD’s Atara Biotherapeutics ATRA Stock Holding History

SignatureFD’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-96
Closed -$3.55K – 3138
2023
Q3 		$3.55K Hold
96
– – ﹤0.01% 2608
2023
Q2 		$3.86K Sell
96
-12
-11% -$679 ﹤0.01% 2602
2023
Q1 		$7.82K Sell
108
-30
-22% -$2.91K ﹤0.01% 2316
2022
Q4 		$11.3K Sell
138
-98
-42% -$10.2K ﹤0.01% 2088
2022
Q3 		$22K Buy
236
+111
+89% +$12.5K ﹤0.01% 1682
2022
Q2 		$24K Buy
125
+21
+20% +$3.43K ﹤0.01% 1674
2022
Q1 		$24K Buy
104
+8
+8% +$2.55K ﹤0.01% 1747
2021
Q4 		$38K Hold
96
– – ﹤0.01% 1459
2021
Q3 		$43K Hold
96
– – ﹤0.01% 1380
2021
Q2 		$37K Hold
96
– – ﹤0.01% 1413
2021
Q1 		$34K Buy
96
+95
+9,500% +$42K ﹤0.01% 1348
2020
Q4 		$1K Buy
+1
New +$462 ﹤0.01% 2384
2020
Q2 		– Sell
-14
Closed -$3K – 2489
2020
Q1 		$3K Buy
+14
New +$4.44K ﹤0.01% 1789

Other funds holding ATRA

EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SignatureFD's ATRA Position: Q4 2023 in Review

SignatureFD sold out of Atara Biotherapeutics (ATRA) in Q4 2023, closing a stake of 96 shares — an estimated $3.55K sold.

SignatureFD first reported a position in ATRA in Q1 2020 and held it in 13 quarters. The position peaked at $43K in Q3 2021. 90 funds tracked by Wall St. Rank hold ATRA as of Q4 2023.

  • SignatureFD reported no remaining Atara Biotherapeutics position as of Q4 2023 after selling out during the quarter.
  • SignatureFD sold 96 Atara Biotherapeutics shares in Q4 2023, an estimated $3.55K.
  • SignatureFD first reported a position in Atara Biotherapeutics in Q1 2020 and held it in 13 quarters.
  • SignatureFD's Atara Biotherapeutics position peaked at $43K in Q3 2021.
  • 90 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2023.

Based on SignatureFD's 13F filing for Q4 2023, filed 1 Feb 2024.